Alnylam Pharmaceuticals (ALNY) — Profile, ISIN & Live Price

Alnylam Pharmaceuticals, Inc. is a prominent American biopharmaceutical company dedicated to the development and commercialization of RNA interference (RNAi) therapeutics aimed at treating genetically defined diseases. Established in 2002 and headquartered in Cambridge, Massachusetts, Alnylam has positioned itself as a leader in the RNAi space, recognized for its innovative approach to addressing complex genetic conditions. The company's portfolio includes several approved therapies that target a range of diseases, showcasing its commitment to advancing the field of genetic medicine. Alnylam's efforts have earned it a place on Forbes' "100 Most Innovative Growth Companies" list, reflecting its significant impact on the biopharmaceutical landscape.

Recently, Alnylam has expanded its strategic partnerships to enhance its market presence and research capabilities. Notably, the company has entered into a commercial partnership with GENESIS Pharma to extend the reach of its RNAi therapeutics into the Nordic region. Additionally, Alnylam has signed a substantial collaboration with Inceptive Nucleics, potentially worth up to $2 billion, aimed at leveraging artificial intelligence for drug discovery. These developments underscore Alnylam's commitment to innovation and collaboration as it seeks to advance its therapeutic offerings and maintain a competitive edge in the rapidly evolving biopharmaceutical industry.